Identification

Name
Propericiazine
Accession Number
DB01608
Type
Small Molecule
Groups
Approved
Description

Propericiazine is a phenothiazine of the piperidine group. It has been shown to reduce pathologic arousal and affective tension in some psychotic patients, while the symptoms of abnormal mental integration are relatively unaffected. It is a sedative phenothiazine with weak antipsychotic properties. It also has adrenolytic, anticholinergic, metabolic and endocrine effects and an action on the extrapyramidal system. It is used as an adjunctive medication in some psychotic patients, for the control of residual prevailing hostility, impulsiveness and aggressiveness. Pericyazine, like other phenothiazines, is presumed to act principally in the subcortical areas, by producing what has been described as a central adrenergic blockade.

Structure
Thumb
Synonyms
  • 10-(3-(4-Hydroxypiperidino)propyl)phenothiazine-2-carbonitrile
  • 2-Cyano-10-(3-(4-hydroxy-1-piperidyl)propyl)phenothiazine
  • 2-Cyano-10-(3-(4-hydroxypiperidino)propyl)phenothiazine
  • Cyano-3 ((hydroxy-4 piperidyl-1)-3 propyl)-10 phenothiazine
  • Periciazina
  • Periciazine
  • Periciazinum
  • Pericyazine
  • Piperocyanomazine
  • Propericiazine
External IDs
RP 8909 / RP-8909 / SKF 20716 / SKF-20716
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Neuleptil 10mg CapsulesCapsule10 mgOralErfa Canada 2012 Inc1969-12-31Not applicableCanada
Neuleptil 20mg CapsulesCapsule20 mgOralErfa Canada 2012 Inc1976-12-31Not applicableCanada
Neuleptil 5mg CapsulesCapsule5 mgOralErfa Canada 2012 Inc1969-12-31Not applicableCanada
Neuleptil Gouttes 10mg/mlSolution / drops10 mgOralErfa Canada 2012 Inc1976-12-31Not applicableCanada
International/Other Brands
Neulactil / Neuleptil
Categories
UNII
3405M6FD73
CAS number
2622-26-6
Weight
Average: 365.492
Monoisotopic: 365.156183063
Chemical Formula
C21H23N3OS
InChI Key
LUALIOATIOESLM-UHFFFAOYSA-N
InChI
InChI=1S/C21H23N3OS/c22-15-16-6-7-21-19(14-16)24(18-4-1-2-5-20(18)26-21)11-3-10-23-12-8-17(25)9-13-23/h1-2,4-7,14,17,25H,3,8-13H2
IUPAC Name
10-[3-(4-hydroxypiperidin-1-yl)propyl]-10H-phenothiazine-2-carbonitrile
SMILES
OC1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C#N)CC1

Pharmacology

Indication

For use as adjunctive medication in some psychotic patients. Propericiazine (Pericyazine)is used for the control of residual prevailing hostility, impulsiveness and aggressiveness.

Structured Indications
Pharmacodynamics

Pericyazine is a phenothiazine of the piperidine group. It has been shown to reduce pathologic arousal and affective tension in some psychotic patients, while the symptoms of abnormal mental integration are relatively unaffected. It is a sedative phenothiazine with weak antipsychotic properties. It also has adrenolytic, anticholinergic, metabolic and endocrine effects, and an action on the extrapyramidal system.

Mechanism of action

Pericyazine, like other phenothiazines, is presumed to act principally in the subcortical areas, by producing what has been described as a central adrenergic blockade of the alpha adrenergic receptors as well as antagonism of the D(1) dopamine receptor.

TargetActionsOrganism
AD(1A) dopamine receptor
antagonist
Human
AAlpha-2A adrenergic receptor
antagonist
Human
UAlpha-1B adrenergic receptor
antagonist
Human
UAndrogen receptorNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

In milder cases of phenothiazine overdosage the patient may be agitated, delirious and confused. Frequently he is lethargic or in a comatose state. Twitching, dystonic movements or convulsions may be present and hypotension, cardiovascular collapse, arrhythmias and hypothermia might be observed.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetaminePropericiazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetaminePropericiazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetaminePropericiazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Propericiazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
AcebutololPropericiazine may increase the hypotensive activities of Acebutolol.Approved
AlaproclateThe risk or severity of adverse effects can be increased when Propericiazine is combined with Alaproclate.Experimental
AlfentanilPropericiazine may increase the hypotensive activities of Alfentanil.Approved, Illicit
AlmasilateAlmasilate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Propericiazine.Approved, Investigational
AloglutamolAloglutamol can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlphacetylmethadolPropericiazine may increase the hypotensive activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodinePropericiazine may increase the hypotensive activities of Alphaprodine.Illicit
AlprenololPropericiazine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AluminiumAluminium can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmantadineThe therapeutic efficacy of Propericiazine can be decreased when used in combination with Amantadine.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Propericiazine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Propericiazine.Approved
AmodiaquineThe serum concentration of Propericiazine can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Propericiazine.Approved
AmphetaminePropericiazine may decrease the stimulatory activities of Amphetamine.Approved, Illicit
ApomorphineThe therapeutic efficacy of Propericiazine can be decreased when used in combination with Apomorphine.Approved, Investigational
ArotinololPropericiazine may increase the hypotensive activities of Arotinolol.Approved, Investigational
ArtemetherThe serum concentration of Propericiazine can be increased when it is combined with Artemether.Approved
ArtemisininThe serum concentration of Propericiazine can be increased when it is combined with Artemisinin.Investigational
ArtemotilThe serum concentration of Propericiazine can be increased when it is combined with Artemotil.Experimental
ArtenimolThe serum concentration of Propericiazine can be increased when it is combined with Artenimol.Approved, Investigational
ArtesunateThe serum concentration of Propericiazine can be increased when it is combined with Artesunate.Approved, Investigational
AtenololPropericiazine may increase the hypotensive activities of Atenolol.Approved
AtovaquoneThe serum concentration of Propericiazine can be increased when it is combined with Atovaquone.Approved
BefunololPropericiazine may increase the hypotensive activities of Befunolol.Experimental
BenzphetaminePropericiazine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
BetaxololPropericiazine may increase the hypotensive activities of Betaxolol.Approved
BevantololPropericiazine may increase the hypotensive activities of Bevantolol.Approved
BezitramidePropericiazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BisoprololPropericiazine may increase the hypotensive activities of Bisoprolol.Approved
BopindololPropericiazine may increase the hypotensive activities of Bopindolol.Approved
BromocriptineThe therapeutic efficacy of Propericiazine can be decreased when used in combination with Bromocriptine.Approved, Investigational
BucindololPropericiazine may increase the hypotensive activities of Bucindolol.Investigational
BufuralolPropericiazine may increase the hypotensive activities of Bufuralol.Experimental, Investigational
BupranololPropericiazine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphinePropericiazine may increase the hypotensive activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Propericiazine.Approved, Investigational
ButorphanolPropericiazine may increase the hypotensive activities of Butorphanol.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Propericiazine.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CarfentanilPropericiazine may increase the hypotensive activities of Carfentanil.Illicit, Investigational, Vet Approved
CarteololPropericiazine may increase the hypotensive activities of Carteolol.Approved
CarvedilolPropericiazine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololPropericiazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChloroquineThe serum concentration of Propericiazine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorphenterminePropericiazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproguanilThe serum concentration of Propericiazine can be increased when it is combined with Chlorproguanil.Investigational
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Propericiazine.Approved
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Propericiazine.Approved, Vet Approved
CloranololPropericiazine may increase the hypotensive activities of Cloranolol.Experimental
CodeinePropericiazine may increase the hypotensive activities of Codeine.Approved, Illicit
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Propericiazine.Approved
Cycloguanil embonateThe serum concentration of Propericiazine can be increased when it is combined with Cycloguanil embonate.Experimental
DapoxetineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Dapoxetine.Investigational
DapsoneThe serum concentration of Propericiazine can be increased when it is combined with Dapsone.Approved, Investigational
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Propericiazine.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Propericiazine.Approved
DextroamphetaminePropericiazine may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Propericiazine.Approved
DextromoramidePropericiazine may increase the hypotensive activities of Dextromoramide.Experimental, Illicit
DextropropoxyphenePropericiazine may increase the hypotensive activities of Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocinePropericiazine may increase the hypotensive activities of Dezocine.Approved, Investigational
DiethylpropionPropericiazine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DihydrocodeinePropericiazine may increase the hypotensive activities of Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Propericiazine.Approved
DihydroetorphinePropericiazine may increase the hypotensive activities of Dihydroetorphine.Experimental, Illicit
DihydromorphinePropericiazine may increase the hypotensive activities of Dihydromorphine.Experimental, Illicit
DiphenoxylatePropericiazine may increase the hypotensive activities of Diphenoxylate.Approved, Illicit
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Propericiazine.Approved
DoxycyclineThe serum concentration of Propericiazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DPDPEPropericiazine may increase the hypotensive activities of DPDPE.Experimental
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Propericiazine.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Propericiazine.Approved, Investigational
EpanololPropericiazine may increase the hypotensive activities of Epanolol.Experimental
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Propericiazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Propericiazine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Propericiazine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Propericiazine.Approved, Investigational
EsmololPropericiazine may increase the hypotensive activities of Esmolol.Approved
EthylmorphinePropericiazine may increase the hypotensive activities of Ethylmorphine.Approved, Illicit
EtorphinePropericiazine may increase the hypotensive activities of Etorphine.Illicit, Vet Approved
FenfluramineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Fenfluramine.Illicit, Investigational, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Propericiazine.Approved, Illicit, Investigational, Vet Approved
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Propericiazine.Approved, Vet Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Propericiazine.Approved, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Propericiazine.Approved, Investigational
GepefrinePropericiazine may decrease the stimulatory activities of Gepefrine.Experimental
HalofantrineThe serum concentration of Propericiazine can be increased when it is combined with Halofantrine.Approved
HeroinPropericiazine may increase the hypotensive activities of Heroin.Approved, Illicit, Investigational
HydrocodonePropericiazine may increase the hypotensive activities of Hydrocodone.Approved, Illicit
HydromorphonePropericiazine may increase the hypotensive activities of Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
HydroxyamphetaminePropericiazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxychloroquineThe serum concentration of Propericiazine can be increased when it is combined with Hydroxychloroquine.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Propericiazine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Indalpine.Investigational, Withdrawn
IndenololPropericiazine may increase the hypotensive activities of Indenolol.Withdrawn
Iofetamine I-123Propericiazine may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Propericiazine.Approved
KetobemidonePropericiazine may increase the hypotensive activities of Ketobemidone.Approved, Investigational
LabetalolPropericiazine may increase the hypotensive activities of Labetalol.Approved
LandiololPropericiazine may increase the hypotensive activities of Landiolol.Investigational
LevobunololPropericiazine may increase the hypotensive activities of Levobunolol.Approved
LevodopaThe therapeutic efficacy of Propericiazine can be decreased when used in combination with Levodopa.Approved
Levomethadyl AcetatePropericiazine may increase the hypotensive activities of Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Propericiazine.Approved
LevorphanolPropericiazine may increase the hypotensive activities of Levorphanol.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Propericiazine.Approved, Investigational
LisdexamfetaminePropericiazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Propericiazine.Approved
LofentanilPropericiazine may increase the hypotensive activities of Lofentanil.Illicit
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Propericiazine.Approved
LumefantrineThe serum concentration of Propericiazine can be increased when it is combined with Lumefantrine.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Propericiazine.Approved
MefloquineThe serum concentration of Propericiazine can be increased when it is combined with Mefloquine.Approved
MephedronePropericiazine may decrease the stimulatory activities of Mephedrone.Investigational
MephenterminePropericiazine may decrease the stimulatory activities of Mephentermine.Approved
MepindololPropericiazine may increase the hypotensive activities of Mepindolol.Experimental
MeptazinolPropericiazine may increase the hypotensive activities of Meptazinol.Experimental
MequitazinePropericiazine may increase the arrhythmogenic activities of Mequitazine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Propericiazine.Approved
Methadyl AcetatePropericiazine may increase the hypotensive activities of Methadyl Acetate.Approved, Illicit
MethamphetaminePropericiazine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethoxyphenaminePropericiazine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Propericiazine is combined with Methylphenidate.Approved, Investigational
MetipranololPropericiazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Propericiazine.Approved, Investigational
MetoprololPropericiazine may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Propericiazine.Approved
MidomafetaminePropericiazine may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Propericiazine.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Propericiazine.Approved
MizoribineThe serum concentration of Propericiazine can be increased when it is combined with Mizoribine.Investigational
MMDAPropericiazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Propericiazine.Approved
MorphinePropericiazine may increase the hypotensive activities of Morphine.Approved, Investigational
NadololPropericiazine may increase the hypotensive activities of Nadolol.Approved
NalbuphinePropericiazine may increase the hypotensive activities of Nalbuphine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Propericiazine.Approved, Investigational
NebivololPropericiazine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Propericiazine.Approved, Withdrawn
NicomorphinePropericiazine may increase the hypotensive activities of Nicomorphine.Experimental
NormethadonePropericiazine may increase the hypotensive activities of Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Propericiazine.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Olanzapine.Approved, Investigational
OpiumPropericiazine may increase the hypotensive activities of Opium.Approved, Illicit
OxprenololPropericiazine may increase the hypotensive activities of Oxprenolol.Approved
OxycodonePropericiazine may increase the hypotensive activities of Oxycodone.Approved, Illicit, Investigational
OxymorphonePropericiazine may increase the hypotensive activities of Oxymorphone.Approved, Investigational, Vet Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Propericiazine.Approved, Investigational
PenbutololPropericiazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentazocinePropericiazine may increase the hypotensive activities of Pentazocine.Approved, Vet Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Propericiazine.Approved
PhenazocinePropericiazine may increase the hypotensive activities of Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Propericiazine.Approved
PhenoperidinePropericiazine may increase the hypotensive activities of Phenoperidine.Experimental
PhenterminePropericiazine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PindololPropericiazine may increase the hypotensive activities of Pindolol.Approved
PiribedilThe therapeutic efficacy of Propericiazine can be decreased when used in combination with Piribedil.Investigational
PiritramidePropericiazine may increase the hypotensive activities of Piritramide.Investigational
Platelet Activating FactorPropericiazine may increase the hypotensive activities of Platelet Activating Factor.Experimental
PractololPropericiazine may increase the hypotensive activities of Practolol.Approved
PramipexoleThe therapeutic efficacy of Propericiazine can be decreased when used in combination with Pramipexole.Approved, Investigational
PrimaquineThe serum concentration of Propericiazine can be increased when it is combined with Primaquine.Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Propericiazine.Approved
ProguanilThe serum concentration of Propericiazine can be increased when it is combined with Proguanil.Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Propericiazine.Approved
PropranololPropericiazine may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Propericiazine.Approved
PseudoephedrinePropericiazine may decrease the stimulatory activities of Pseudoephedrine.Approved
PyrimethamineThe serum concentration of Propericiazine can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
PyronaridineThe serum concentration of Propericiazine can be increased when it is combined with Pyronaridine.Investigational
QuinacrineThe serum concentration of Propericiazine can be increased when it is combined with Quinacrine.Approved, Investigational
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Propericiazine.Approved
QuinidineThe serum concentration of Propericiazine can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Propericiazine can be increased when it is combined with Quinine.Approved
RadicicolThe serum concentration of Propericiazine can be increased when it is combined with Radicicol.Experimental
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Propericiazine.Approved
RemifentanilPropericiazine may increase the hypotensive activities of Remifentanil.Approved
RitobegronPropericiazine may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Propericiazine.Approved
RopiniroleThe therapeutic efficacy of Propericiazine can be decreased when used in combination with Ropinirole.Approved, Investigational
RotigotineThe therapeutic efficacy of Propericiazine can be decreased when used in combination with Rotigotine.Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Propericiazine.Approved, Investigational, Vet Approved
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Propericiazine.Approved
SinefunginThe serum concentration of Propericiazine can be increased when it is combined with Sinefungin.Experimental
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SotalolPropericiazine may increase the hypotensive activities of Sotalol.Approved
SufentanilPropericiazine may increase the hypotensive activities of Sufentanil.Approved, Investigational
SulfadoxineThe serum concentration of Propericiazine can be increased when it is combined with Sulfadoxine.Approved, Investigational
SulfametopyrazineThe serum concentration of Propericiazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulpirideThe risk or severity of adverse effects can be increased when Propericiazine is combined with Sulpiride.Approved, Investigational
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Propericiazine.Approved, Investigational
tafenoquineThe serum concentration of Propericiazine can be increased when it is combined with tafenoquine.Investigational
TalinololPropericiazine may increase the hypotensive activities of Talinolol.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Propericiazine.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Propericiazine.Approved
TertatololPropericiazine may increase the hypotensive activities of Tertatolol.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Propericiazine.Approved
ThiopentalThe risk or severity of adverse effects can be increased when Propericiazine is combined with Thiopental.Approved, Vet Approved
TilidinePropericiazine may increase the hypotensive activities of Tilidine.Experimental
TimololPropericiazine may increase the hypotensive activities of Timolol.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Propericiazine.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Propericiazine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Propericiazine.Approved, Investigational
TrimethoprimThe serum concentration of Propericiazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Propericiazine.Approved
TromethamineTromethamine can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Propericiazine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Propericiazine.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Propericiazine.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Propericiazine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Zimelidine.Withdrawn
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Propericiazine.Approved, Investigational
Food Interactions
  • Take with food to reduce irritation. Avoid alcohol.

References

General References
Not Available
External Links
Human Metabolome Database
HMDB15546
KEGG Drug
D01485
PubChem Compound
4747
PubChem Substance
46505085
ChemSpider
4585
BindingDB
50346422
ChEBI
31981
ChEMBL
CHEMBL251940
Therapeutic Targets Database
DAP000413
PharmGKB
PA164781043
ATC Codes
N05AC01 — Periciazine
AHFS Codes
  • 28:16.08.24 — Phenothiazines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Unknown StatusTreatmentPsychosis Nos/Other1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral10 mg
CapsuleOral20 mg
CapsuleOral5 mg
Solution / dropsOral10 mg
Prices
Unit descriptionCostUnit
Neuleptil 20 mg Capsule0.52USD capsule
Neuleptil 10 mg/ml Drops0.41USD ml
Neuleptil 10 mg Capsule0.34USD capsule
Neuleptil 5 mg Capsule0.21USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)116-117 °CPhysProp
water solubility38 mg/L (at 37 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.52HANSCH,C ET AL. (1995)
logS-3.98ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.059 mg/mLALOGPS
logP3.78ALOGPS
logP3.11ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)15.18ChemAxon
pKa (Strongest Basic)8.37ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area50.5 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity108.4 m3·mol-1ChemAxon
Polarizability40.87 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9747
Blood Brain Barrier+0.9691
Caco-2 permeable+0.5608
P-glycoprotein substrateSubstrate0.6582
P-glycoprotein inhibitor IInhibitor0.8072
P-glycoprotein inhibitor IIInhibitor0.6046
Renal organic cation transporterInhibitor0.6545
CYP450 2C9 substrateNon-substrate0.7657
CYP450 2D6 substrateSubstrate0.6233
CYP450 3A4 substrateNon-substrate0.6064
CYP450 1A2 substrateInhibitor0.6843
CYP450 2C9 inhibitorNon-inhibitor0.8852
CYP450 2D6 inhibitorInhibitor0.6558
CYP450 2C19 inhibitorNon-inhibitor0.8539
CYP450 3A4 inhibitorNon-inhibitor0.8952
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7203
Ames testNon AMES toxic0.6802
CarcinogenicityNon-carcinogens0.9537
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9345 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7341
hERG inhibition (predictor II)Inhibitor0.6604
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-03xu-7932000000-163720fa7ee8e5adf313
GC-MS Spectrum - EI-BGC-MSsplash10-03di-4931000000-bc6eaf361b17af48a30f
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Phenothiazines
Direct Parent
Phenothiazines
Alternative Parents
Alkyldiarylamines / Diarylthioethers / Piperidines / Benzenoids / 1,4-thiazines / Trialkylamines / Secondary alcohols / Nitriles / Azacyclic compounds / Organopnictogen compounds
show 1 more
Substituents
Phenothiazine / Alkyldiarylamine / Diarylthioether / Aryl thioether / Tertiary aliphatic/aromatic amine / Para-thiazine / Piperidine / Benzenoid / Secondary alcohol / Tertiary aliphatic amine
show 14 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
phenothiazines, nitrile, hydroxypiperidine (CHEBI:31981)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Kanba S, Suzuki E, Nomura S, Nakaki T, Yagi G, Asai M, Richelson E: Affinity of neuroleptics for D1 receptor of human brain striatum. J Psychiatry Neurosci. 1994 Jul;19(4):265-9. [PubMed:7918347]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Tsukamoto T, Asakura M, Hirata N, Imafuku J, Matsui H, Hasegawa K: Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91. [PubMed:6149771]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
Gene Name
AR
Uniprot ID
P10275
Uniprot Name
Androgen receptor
Molecular Weight
98987.9 Da
References
  1. Bisson WH, Cheltsov AV, Bruey-Sedano N, Lin B, Chen J, Goldberger N, May LT, Christopoulos A, Dalton JT, Sexton PM, Zhang XK, Abagyan R: Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11927-32. Epub 2007 Jul 2. [PubMed:17606915]

Drug created on August 29, 2007 12:52 / Updated on December 10, 2017 17:18